Strategic discussion on funding and access to therapies targeting rare diseases in Spain: an expert consensus paper.

Background: In recent years, significant advances have been made in the field of rare diseases (RDs). However, there is a large number of RDs without specific treatment and half of these treatments have public funding in Spain. The aim of the FINEERR project was to carry out a multidisciplinary strategic discussion on the challenge of funding and access to RD-targeted drugs in Spain, in order to agree on specific proposals for medium-term improvement and hence support decision-making in the Spanish National Healthcare System (SNHS).

Clinical response to growth hormone in children with intrauterine growth retardation without catch-up growth in Castilla y León (Spain).

Introduction And Objectives: Growth hormone (rhGH) is used in children with intrauterine growth retardation without catch-up growth. The Advisory Committee of Castilla y León was implemented in 2010 to watch for consistent application of the criteria for using rhGH. The aim is to assess anthropometric and clinical changes in children treated with growth hormone.

[Smoking impact on mortality in Spain in 2012].

Background And Objective: Smoking is an important public health problem, and is one of the main avoidable causes of morbidity and early mortality. The aim was to estimate the mortality attributable to smoking and its impact on premature mortality in Spain in the year 2012.

Patients And Methods: Descriptive, cross-sectional study, carried out on the Spanish population aged ≥ 18 years in 2012.